Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)
Unresectable low grade glioma (LGG) of childhood increasingly appears as a chronic condition
for which multiple treatments may be required. While several studies have shown evidence of
short term tumour control with chemotherapy, the progression-free survival at 5 years is
unsatisfactory. In addition, several regimens currently used for this condition are
associated with significant risks of side effect and long term toxicity.
We have piloted in a single arm study the feasibility and efficacy of Vinblastine for
children with recurrent and refractory low grade glioma, who have failed at least one line
of treatment (chemotherapy and/or irradiation). Preliminary results show promising activity
with minimal toxicity.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The response rate to weekly vinblastine
70 Weeks
No
Eric Bouffet, MD
Study Chair
The Hospital for Sick Children, Toronto Canada
Canada: Health Canada
1000011227
NCT00575796
October 2007
October 2018
Name | Location |
---|